Lung Cancer Vaccines and Therapeutic Antibodies: Pipeline, Strategies and Clinical

07 Oct 2011 • by Natalie Aster

New lung cancer immunotherapies are being progressed by more than 60 organisations, 80% of which are SMEs or non-commercial research departments.

Immunotherapy strategies are seeing success and failure; giving insights that reduce risk and improve decision-making in R&D and commercial departments.

Development strategies are being progressed by more than 60 organisations, together with partnerships and collaborations in this dynamic field.

It is believed that cancer vaccines will offer improved strategies for targeting lung cancer. The report “Lung Cancer Vaccines and Therapeutic Antibodies: Pipeline, Strategies and Clinical” by Biopharm Reports provides developmental and market- related perspectives in this promising and rapidly developing field. It presents a diverse and complex emerging field, in an accessible and easy-to-read format.

Report Details:

Lung Cancer Vaccines and Therapeutic Antibodies: Pipeline, Strategies and Clinical
Published: October 2011
Pages: 186
Price: US$ 2,384.00

Report Sample Abstract

For decades, lung cancer has remained the most common cancer worldwide. Survival rates, while improved in recent decades, are poor compared to almost all other cancers. US studies (2006) found that lung cancer care costs were the third highest of all cancers, while indirect costs (2005) were higher than for any other cancer.

Patient needs and the high burden of lung cancer on society drive the development of new treatments. While improvements have been seen in diagnosis and in treatments such as surgery, radiotherapy, chemotherapy and targeted drugs, advances that build on the capabilities of existing therapies, are urgently required.

Today, advances continue to be made in drug treatments for lung cancer, including chemotherapy and other small molecule approaches, and in targeted drugs. In particular, rapid developments are being seen in the field of immunotherapy, notably in therapeutic antibodies and vaccines.

More information can be found in the report “Lung Cancer Vaccines and Therapeutic Antibodies: Pipeline, Strategies and Clinical” by Biopharm Reports.

Related reports:

• Lung Cancer Therapeutic Antibodies: Pipeline, Strategies and Clinical;
• Lung Cancer Vaccines: Pipeline, Strategies and Clinical.

To order the report or ask for sample pages contact [email protected]

Contacts

MarketPublishers, Ltd.
Tanya Rezler
Tel: +44 208 144 6009
Fax: +44 207 900 3970
[email protected]
www.MarketPublishers.com